1Caussanel J P, Levi F, Brienza S, et al. Phase Ⅰ trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm - modulated rate compared with constant rate[J]. J Natl Cancer Inst, 1990, 82(12) : 1046 - 1050.
2Feliu J, Salud A, Escudero P,et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer[ J]. Br J Cancer, 2006, 94(7) : 969 - 975.
3Comella P,Natale D, Farris A,et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108[J]. Cancer, 2005, 104(2) : 282 -289.
5Cassidy J, Tabernero J, Twelves C, et al. XELOX ( capecitabine plus oxaliplatin) : active first-line therapy for patients with metastatic colorectal cancer[J]. J Clin Oncol, 2004, 22( 11 ) : 2084 -2091.
6Twelves C J, Butts C A, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase Ⅱ study[J]. Clin Colorectal Cancer, 2005, 5(2) : 101 -107.
2Burdy G,Panis Y,Alves A,et al.Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence[J].Dis Colon Rectum,2001,44(11):1682-1688.
3Killingback M,Barron P,Dent O F.Local recurrence after curative resection of cancer of the rectum without total mesorectal excision[J].Dis Colon Rectum,2001,44(4):473-483.
4Park Y J,Park K J,Park J G,et al.Prognosis factor in 2230 Korean colorectal cancer patients:analysis of consecutively operated cases[J].World J Surg,1999,23(7):721-726.
5Roncucci L,Fante R,Losi L,et al.Survival for colon and rectal cancer in a population based cancer registry[J].Eur J Cancer,1996,32A(2):295-302.
6Kraemer M,Wiratkapun S,Seow-Choen F,et al.Stratifying risk factors for follow-up:a comparison of recurrent and nonrecurrent colorectal cancer[J].Dis Colon Rectum,2001,44(6):815-821.
7Mulcahy H E,Toner M,Patchett S E,et al.Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death[J].Dis Colon Rectum,1997,40(3):326-331.
8Walker J,Quirke P.Prognosis and response to therapy in colorectal cancer[J].Eur J Cancer,2002,38(7):880-886.
4Ferlay J,Bray F,Pisani P,Parkin DM.GLOBOCAN 2000 Cancer Incidence,Mortality and Prevalence Worldwide[R].Version I.O.IARC Cancer Base No 5.Lyon IARC 2001.
5Raymond E,Buquet-Fagot C,et al.Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon,breast,and ovarian cancers[J].Anticancer Drugs,1997,8:876.
6Diaz-Rubio E,Sastre J,Zaniboni A,et al.Oxaliplatin as single agent in previously untreated colorectal caxinomx,patients a phase II multicentric study[J].Ann Oncol,1998,9(1):105.
7De Gramont A,Figer A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18:2938.
8Chickpetty S M,Baswaraj R,Sunil K G.Development of Novel Combined Time and pH-Dependent Based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon[J].Curr Drug Deliv,2011,[Epub ahead of print].
9Blum M,Suzuki A,Ajani JA.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma[J].Future Oncol,2011,7(6):715.
10Chollet P,Schoffski P,Weigang-Kohler K,et al.Phase Ⅱ trialwith S-1 in chemotherapy-nave patientswith gastric cancer.A trial performed by the EORTC Early Clinical Studies Group(ECSG)[J].EurJ Cancer,2003,39(9):1264.
